Cargando...
A “triple whammy” in adenocarcinoma lung
Osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI), is useful in the treatment of non-small cell lung cancer who show resistance to first-generation EGFR-TKIs and harbor T790M mutation. Acquisition of resistance to osimertinib due to sev...
Gardado en:
| Publicado en: | Lung India |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Wolters Kluwer - Medknow
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6625246/ https://ncbi.nlm.nih.gov/pubmed/31290421 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/lungindia.lungindia_212_18 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|